title: Allogeneic hemopietic stem cell transplants for the treatment of B cell acute lymphocytic leukemia.
abstract: OBJECTIVE
  Explore the feasibility of allo- hemopietic stem cell transplants in treating patients with B cell acute lymphocytic leukemia.
  
  
  METHODS
  Between september 2006 and February 2011, fifteen patients with B cell acute lymphocytic leukemia (ALL) were treated by allo-hemopietic stem cell transplants (HSCT). Stem cell sources were peripheral blood. Six patients were conditioned by busulfan (BU) and cyclophosphamide (CY) and nine patients were conditioned with TBI and cyclophosphamide (CY). Graft versus host disease (GVHD) prophylaxis regimen consisted of cyclosporine A (CSA), methotrex ate (MTX) and mycophenolatemofetil (MMF).
  
  
  RESULTS
  Patients received a median of 7.98×10⁸·kg⁻¹ (5.36-12.30×10⁸·kg⁻¹) mononuclear cells (MNC). The median time of ANC>0.5×10⁹/L was day 12 (10-15), and PLT>20.0×10⁹/L was day 13 (11-16). Extensive acute GVHD occurred in 6 (40.0%) patients, and extensive chronic GVHD was recorded in 6 (40.0%) patients. Nine patients were alive after 2.5-65 months follow-up.
  
  
  CONCLUSIONS
  Allogeneic stem cell transplant could be effective in treating patients with B cell acute lymphocytic leukemia.
authors.affiliation: Department of Hematology, The First People's Hospital of Changzhou, Third Affiliated Hospital of Suzhou University, Changzhou, Jiangsu, China E-mail : weimindong19891989@126.com.
authors.forename: Wei-Min
authors.initials: WM
authors.lastname: Dong
authors.forename: Xiang-Shan
authors.initials: XS
authors.lastname: Cao
authors.forename: Biao
authors.initials: B
authors.lastname: Wang
authors.forename: Yun
authors.initials: Y
authors.lastname: Lin
authors.forename: Xiao-Ying
authors.initials: XY
authors.lastname: Hua
authors.forename: Guo-Qiang
authors.initials: GQ
authors.lastname: Qiu
authors.forename: Wei-Ying
authors.initials: WY
authors.lastname: Gu
authors.forename: Xiao-Bao
authors.initials: XB
authors.lastname: Xie
mesh_terms: D000328:Adult; D002681:China / Q000453:epidemiology; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000453:epidemiology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D015996:Survival Rate; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents